DakoCytomation Acquires Gastric Ulcer Test

By HospiMedica staff writers
Posted on 15 Sep 2003

The rights to a test detecting the ulcer-causing bacteria Helicobactor pylori have been acquired by DakoCytomation (Copenhagen, Denmark) from Connex GmbH (Martinsried, Germany), a biotechnology company.

According to the agreement, DakoCytomation will handle continued production, sales, distribution, and customer service of the test, which will become part of DakoCytomation's diagnostic portfolio. The H pylori antibodies are used in a test that is an enzyme-linked immunosorbent assay (ELISA). Compared to other tests, this method is noninvasive and because it is cost effective, more patients will be able to receive optimal treatment, states DakoCytomation.

"Acquisition of the H pylori rights is strategically important to us; we continuously aim at expanding and strengthening our proprietary pool of key intellectual property rights to better serve our customers and secure our continued development and growth,” said Erik Winther, executive vice president and CFO of DakoCytomation.

Related Links:
DakoCytomation
Connex